Results 81 to 90 of about 3,144,476 (264)

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
A Husain, A Sancar, B Stordal, BK Stordal, Britta Stordal, C Richardson, CH Hensel, DW Melton, E Raderschall, ER McDonald III, ES Child, F Nunez, FM Wachters, G Bepler, H Lincet, HD Preisler, IY Chang, JC Harrison, JJ Yu, JS Russell, K Rothkamm, KA Olaussen, KM Darcy, L Poulain, LF Qin, LF Qin, M Dabholkar, M Takata, M Takata, PA Havre, PA Havre, R Altaha, R Napieralski, R Rosell, RG Sargent, RG Syljuasen, Ross Davey, RVN Lord, S Henness, S Rozen, SG Chaney, T Hata, TT Paull, Y Yonetani   +43 more
core   +2 more sources

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines

Molecular Cancer, 2011
Background YB-1 is a multifunctional protein that affects transcription, splicing, and translation. Overexpression of YB-1 in breast cancers causes cisplatin resistance. Recent data have shown that YB-1 is also overexpress in colorectal cancer.
Tsofack Serges P, Garand Chantal, Sereduk Chris, Chow Donald, Aziz Meraj, Guay David, Yin Hongwei H, Lebel Michel   +7 more
doaj   +1 more source

E2F1 inhibits cellular senescence and promotes oxaliplatin resistance in colorectal cancer

Annals of Translational Medicine, 2023
Doctors have always been overwhelmed by tumor drug resistance because it is a major challenge in the clinical treatment of tumors. Cellular senescence has a strong relationship with the development of tumor drug resistance. Herein, we aimed to explore new regulatory factors involved in the aging process of colorectal cancer (CRC) cells and assess the ...
Gao, Haiyang, Zhou, Fangyuan, Li, Runze, Yuan, Jiao, Ye, Lin   +4 more
openaire   +2 more sources

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui, Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, Mary Kay Washington, Kamran Idrees   +6 more
wiley   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Oxaliplatin resistance limits the efficiency of treatment for colorectal cancer (CRC). Studies have shown that abnormal expression of microRNAs (miRNAs) were associated with tumorigenesis, cancer development and chemoresistance. The purpose of this study
Hui Liang, Yisong Xu, Qiang Zhang, Yu Yang, Yueyang Mou, Yingchun Gao, Rui Chen, Chao Chen, Penggao Dai   +8 more
doaj   +1 more source

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. [PDF]

, 2020
PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model ...
Bouvet, Michael, Clary, Bryan, Han, Qinghong, Hoffman, Robert M, Singh, Shree Ram, Sun, Yu, Tan, Yuying, Ye, Jianxin, Zhao, Ming, Zhu, Guangwei   +9 more
core  

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer

Biomedicines, 2022
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug ...
Sun Young Park, Ye Seo Chung, So Yeon Park, So Hee Kim   +3 more
openaire   +3 more sources